{"id":"enoxaparin-sodium-injection-rivaroxaban-tablets","safety":{"commonSideEffects":[{"rate":"2-5%","effect":"Major bleeding"},{"rate":"1-3%","effect":"Hemorrhage"},{"rate":"1-2%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Enoxaparin sodium injection is a low molecular weight heparin that exerts its anticoagulant effect by binding to antithrombin III, thereby inhibiting Factor Xa and Factor IIa. Rivaroxaban tablets, on the other hand, directly inhibits Factor Xa, a key enzyme in the coagulation cascade. This dual mechanism of action helps prevent the formation of blood clots and reduce the risk of stroke and other thromboembolic events.","oneSentence":"Enoxaparin sodium injection works by inhibiting Factor Xa and Factor IIa, preventing blood clot formation, while rivaroxaban tablets inhibit Factor Xa directly.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:51:01.523Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis and treatment of deep vein thrombosis, pulmonary embolism, and stroke prevention in atrial fibrillation"}]},"trialDetails":[{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":"Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","enrollment":100},{"nctId":"NCT06220123","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery","status":"COMPLETED","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2024-02-16","conditions":"Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery","enrollment":225},{"nctId":"NCT04169269","phase":"PHASE4","title":"Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban","status":"UNKNOWN","sponsor":"Florida Orthopaedic Institute","startDate":"2020-01-13","conditions":"Deep Vein Thrombosis, Venous Thromboembolism","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Enoxaparin Sodium Injection; Rivaroxaban Tablets","genericName":"Enoxaparin Sodium Injection; Rivaroxaban Tablets","companyName":"Beijing Suncadia Pharmaceuticals Co., Ltd","companyId":"beijing-suncadia-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin sodium injection works by inhibiting Factor Xa and Factor IIa, preventing blood clot formation, while rivaroxaban tablets inhibit Factor Xa directly. Used for Prophylaxis and treatment of deep vein thrombosis, pulmonary embolism, and stroke prevention in atrial fibrillation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}